Blue Lunula Related with Hydroxyurea
Journal Title: Turkish Journal of Hematology - Year 2013, Vol 30, Issue 1
Abstract
Hydroxyurea, which is an inhibitor of ribonucleoside reductase and is used as a systemic antitumor agent, is frequently used for the treatment of myeloproliferative and hematologic diseases. While the most common side effect is myelosuppression, gastrointestinal symptoms such as nausea,vomiting, stomatitis, and anorexia and rash, skin ulcers,hyperpigmentation in nails, and dermatologic toxicities like facial erythema may also be observed. At higher dosages,neurologic symptoms may be rarely seen (1,2).
Authors and Affiliations
Hava Teke, Abdülsamet Erden
Keywords
Related Articles
- EP ID EP105716
- DOI 10.4274/tjh.2011.0016
- Views 71
- Downloads 0
Adsorptive Leukocytapheresis in Inflammatory Bowel Diseases: Our Preliminary Results are Encouraging
To the Editor, Infl ammatory bowel disease (IBD), consisting of ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic recurrent disorder with unclear etiology. A close relation to autoimmune status featured by...
Kronik Miyelomonositik Lösemide Auer Çubukları Tanıyı Değiştirebilir
Thiopurine S-Methyltransferase and Methylenetetrahydrofolate Reductase Polymorphisms in Leukemia
Disappearance of Acquired Hemophilia A after Complete Remission in a Multiple Myeloma Patient
Disappearance of Acquired Hemophilia A after Complete Remission in a Multiple Myeloma Patient
Low HbA2 Level in β-Thalassemia Trait
To the Editor, Dr. Köseler and her colleagues reported the presence of δ- thalassemia in 3 out of 12 patients carrying the β-thalassemia trait with low HbA2 in the recent issue of this journal without giving any explana...